Date:
Wed, 01 Jul 2026 09:28:22 EDT
Content:
The U.S. Food and Drug Administration (FDA) has released a Form 483 following an inspection of the QuVA Pharma Inc. facility located in Sugar Land, Texas. The document, issued on May 4, 2026, outlines specific observations made by FDA investigators regarding the site’s compliance with manufacturing and safety standards.
A Form 483 is typically issued at the conclusion of an inspection when investigators have observed conditions that may constitute violations of the Food, Drug, and Cosmetic Act. For outsourcing facilities and compounding pharmacies, these observations often focus on sterile processing environments, quality control procedures, and equipment maintenance.
The report has been made available through the FDA’s OII FOIA Electronic Reading Room as part of the agency’s commitment to transparency. QuVA Pharma is expected to provide a formal response to the FDA detailing their planned corrective actions to address the concerns identified during the inspection.
Source: FDA Electronic Reading Room
Link:
http://www.fda.gov/about-fda/fda-commissioner/quva-pharma-inc-sugar-land-tx-483-issued-5042026
Keywords:
FDA 483, QuVA Pharma Inc, Sugar Land Texas, Pharmaceutical Inspection, Drug Safety, Compounding Pharmacy, OII FOIA